Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

類似資料

• Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
  著者:: Knudson, Karin M., 等
  出版事項: (2019)
• Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
  著者:: Ozawa, Yohei, 等
  出版事項: (2021)
• M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
  著者:: Knudson, Karin M., 等
  出版事項: (2018)
• The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex
  著者:: Jochems, Caroline, 等
  出版事項: (2018)
• Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy
  著者:: Hicks, Kristin C., 等
  出版事項: (2019)